Nanobiotix S.A.

Nanobiotix S.A. (NANO) priced its initial public offering on Dec 11, 2020 at $13.50 per ADS, within its $13.50–$14.50 range, raising $98.5M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $450.1M. Jefferies was lead-left underwriter, joined by Evercore ISI and UBS.

Nanobiotix S.A. is a clinical-stage biotechnology company developing nanotechnology to increase the efficacy of radiotherapy. Its lead candidate, NBTXR3, is a suspension of hafnium oxide nanoparticles injected directly into tumors before radiotherapy, and has been given to more than 230 patients across eight clinical trials.

Status

IPO

Ticker

NANO

Exchange

Nasdaq Global Select

Priced

Dec 11, 2020

IPO price

$13.50 per ADS

Price range

$13.50–$14.50

Raised

$98.5M

Market cap at IPO price

$450.1M

First filed

Nov 20, 2020

Underwriters

Jefferies, Evercore ISI and UBS

Sector

Biotech & pharma

Country / state

France

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.